TOKYO, Mar 09 (Pulse News Wire) – Renascience Inc. (4889.T) secured funding from the Japan Agency for Medical Research and Development (AMED) for its Phase II trial aimed at evaluating the efficacy and safety of combining its PAI-1 inhibitor drug, RS5614, with chemoradiotherapy and immunotherapy Durvalumab for locally advanced non-small cell lung cancer patients.
The study, led by Hiroshima University Hospital, is scheduled to run from April 01, 2026, to March 31, 2030, with estimated costs of ¥78 million for fiscal year 2026. The trial seeks to enhance the therapeutic effects of chemoradiotherapy and Durvalumab while mitigating associated pulmonary side effects. Previous research demonstrated that RS5614 could increase tumor suppression when combined with radiotherapy in mouse models. Additionally, preliminary data indicate that RS5614 can overcome resistance to chemotherapy and improve immune checkpoint therapy effectiveness.
The trial will involve 27 patients across 12 medical institutions, focusing on improving progression-free survival rates and reducing treatment-related complications. Registration for the trial is set to begin in April 2026 and conclude by March 2028, followed by an observation period until June 2029. While there will be no immediate impact on Renascience's fiscal year 2026 earnings, the company anticipates improved profitability from 2027 to 2029 due to reduced expenses. Full-year forecasts for fiscal 2027 will account for allocated research funds.
🟢 Confidence: High AI-translated content.